Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln into the advancement of Summit’s precision drug ridinilazole for the treatment of C. difficile infection (CDI), taking the total value of the award to $72.5mln.
Summit Therapeutics pleased with new BARDA partnership investment
Quick facts: Summit Therapeutics PLC
Price: 20.5 GBX
Market Cap: £68.91 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE